Third Leading Cause News Today

WASHINGTON, March 11, 2024--U.S. Representatives Nanette Barragán (D-CA) and Michael Burgess (R-TX) have announced the reintroduction of the National Patient Safety Board Act, legislation to establish a public-private research and development team within the Department of Health and Human Services that is solely dedicated to preventing and reducing healthcare-related harms. This landmark bipartisan legislation, announced during Patient Safety Awareness Week, is a critical step to improve sa...

The Pagan Law Firm Shares Expert Tips on Selecting the Perfect Medical ...

FinancialContent fully hosted finance channel

NEW YORK, NY / ACCESSWIRE / June 5, 2023 / Each year thousands of New York residents find themselves facing the aftermath of medical malpractice, ranging from minor injuries to severe bodily harm or death.

If the COVID shots are as bad as they appear, why isn't your doctor warning you about all ...

Respect and admiration is owed to those dissenting doctors who have been persecuted for challenging the official Covid narrative.

Imagine calling out 'misinformation spreaders' for two years, then publishing updated guidance matching exactly what those spreaders been ...

The 2021 death rate was the highest since 2003, the CDC said.

Federal health researchers report the study from the past year. By Shereen Hashem Apr 02, 2021 Following heart disease and cancer, COVID-19 was officially the third leading cause of death in 2020. This displaced unintentional injuries as the usual third place spot, federal health researchers reported. Coronavirus took 345,323 lives of Americans solely last year. According to the National Center for Health Statistics, in about 30,000 additional cases, death certificates cited COVID-19, however, ...

Bemarituzumab is a Strong Strategic Fit With Amgen’s Innovative Oncology Portfolio Amgen to Host Investor Call at 10:30 a.m. EST THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., March 4, 2021 – Amgen (NASDAQ: AMGN) and Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, today announced an agreement under which Amgen will acquire Five Prime Therapeutics for $38.00 per share in cash, represen...